Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

1. An olutasidenib oral unit dosage form comprising olutasidenib in a crystalline form, and having a total of 150 mg olutasidenib in the unit dosage form.

2. The unit dosage form of claim 1 , further comprising a 50-100 micrometer particle size filler blended with the olutasidenib.

3. The unit dosage form of claim 2 , wherein the filler comprises microcrystalline cellulose.

4. The unit dosage form of claim 2 , wherein the filler is microcrystalline cellulose.

5. The unit dosage form of claim 4 , wherein the unit dosage form further comprises the filler and the olutasidenib in a relative weight ratio of about 61:33.

6. The unit dosage form of claim 1 , further comprising a disintegrant blended with the olutasidenib.

7. The unit dosage form of claim 6 , wherein the disintegrant is croscarmellose sodium.

8. The unit dosage form of claim 7 , wherein the unit dosage form further comprises the disintegrant and the olutasidenib in a relative weight ratio of about 5:33.

9. The unit dosage form of claim 1 , further comprising a filler and a disintegrant blended with the olutasidenib.

10. The unit dosage form of claim 9 , wherein the filler is microcrystalline cellulose NF/EP, and the disintegrant is croscarmellose sodium NF/EP.

11. The unit dosage form of claim 10 , wherein the unit dosage form comprises the olutasidenib, filler and disintegrant in a relative weight ratio of about 33:61:5.

12. The unit dosage form of claim 11 , wherein the unit dosage form is a capsule.

13. The unit dosage form of claim 1 , wherein the unit dosage form is a capsule.

14. A 150 mg dosage strength olutasidenib oral capsule unit dosage form comprising a total of 150 mg of micronized olutasidenib active pharmaceutical ingredient in a crystalline form enclosed in the oral capsule unit dosage form.

15. The capsule unit dosage form of claim 14 , further comprising a microcrystalline cellulose filler and a croscarmellose sodium disintegrant blended with the olutasidenib.

16. The capsule unit dosage form of claim 15 , wherein the unit dosage form comprises the olutasidenib, filler and disintegrant in a relative weight ratio of about 33:61:5.

17. The capsule unit dosage form of claim 16 , wherein the unit dosage form is a size 00 capsule.

18. The capsule unit dosage form of claim 14 , wherein the unit dosage form is a size 00 capsule.

19. A 150 mg dosage strength olutasidenib oral capsule unit dosage form comprising a total of 150 mg of micronized olutasidenib active pharmaceutical ingredient in a crystalline form blended with one or more excipients in a relative weight ratio of about 33:67.

20. The olutasidenib oral capsule unit dosage form of claim 19 , wherein the excipients are selected from the group consisting of: a microcrystalline cellulose filler and a croscarmellose sodium disintegrant blended with the olutasidenib.

21. A pharmaceutical composition comprising a capsule containing about 150 mg of olutasidenib in crystalline form.

22. The pharmaceutical composition of claim 21 , wherein the olutasidenib is micronized.

23. The pharmaceutical composition of claim 22 , further comprising one or more excipients selected from the group consisting of a filler, a disintegrant, a lubricant, and a glidant.

24. The pharmaceutical composition of claim 23 , wherein the filler is microcrystalline cellulose.

25. The pharmaceutical composition of claim 23 , wherein the disintegrant is croscarmellose sodium.

26. The pharmaceutical composition of claim 23 , wherein the lubricant is magnesium stearate.

27. The pharmaceutical composition of claim 23 , wherein the glidant is colloidal silicon dioxide.